Compliance: The impact of adverse events and tolerability on the physician's treatment decisions

European Neuropsychopharmacology

Volumn 13, Issue SUPPL. 3, 2003, Pages 85-92

  Roose, Steven P ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

Author keywords

Antidepressants; Compliance; Mirtazapine; RemeronSolTab ; SNRIs; SSRIs; Tolerability

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; APPETITE DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DOCTOR PATIENT RELATION; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; HUMAN; HYPERTENSION; LONG TERM CARE; MEDICAL DECISION MAKING; MEMORY DISORDER; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTPATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; WEIGHT GAIN; XEROSTOMIA;

EID: 0141756312     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00097-X     Document Type: Conference Paper

References (46)

1. Andersen O., Zweidorff O.K., Hjelde T., Rodland E.A. Problems when swallowing tablets. A questionnaire study from general practice. Tidsskr. Nor. Laegeforen. 20:1995;947-949.
2. Anon, 2001. Remeron® SolTab™. Drugs Fut. 25, pp. 1211.
3. Practice Guideline for the Treatment of Patients with Major Depressive Disorders. 2nd Edition: 2000;American Psychiatric Association, Washington, DC.
4. Barbey J.B., Roose S.P. SSRI safety in overdose. J. Clin. Psychiatry. 59:(Suppl. 15):1998;42-48.
5. Beique J., de Montigny C., Blier P., Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in rat. Neuropsychopharmacology. 39:2000;1800-1812.
6. Benkert O., Szegedy A., Kohnen R. Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry. 61:2000;656-663.
7. Brown W.A., Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry. 56:1995;30-34.
8. Bull S.A., Hu X.H., Hunkeler E.M., Lee J.Y., Ming E.E., Markson L.E., Fireman B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. J. Am. Med. Assoc. 288:2002;1403-1409.
9. Cash T.F., Brown M.A. Attitudes about antidepressants: influence of information about weight-related side effects. Percpt. Mot. Skills. 90:2000;453-456.
10. Coulehan J.L., Schulberg H.C., Block M.R., Janoski J.E., Arena W.C. Depressive symptomatology and medical co-morbidity in a primary care setting. Int. J. Psychiatry Med. 20:1990;335-347.
11. Data on File, Organon NV, Molenstraat 110, 5430BH Oss, The Netherlands.
12. 2 selective adrenoceptor Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum. Psychopharmacol. 10:(Suppl. 2):1995;S107-118.
13. Demyttenaere K., Mesters P., Boulanger B., Dewe W., Delsemme M.-H., Gregoire J., Van Ganse E. Adherence to treatment regimen in depressed patients treated with amitriptyline and fluoxetine. J. Affect. Disord. 65:2001;243-252.
14. Demyttenaere K. Compliance during treatment with antidepressants. J. Affect. Disord. 43:1997;27-39.
15. Demyttenaere K. Noncompliance with antidepressants: who's to blame? Int. Clin. Psychopharmacol. 13:(Suppl. 2):1998;S19-S25.
16. DeVane C.L. Principles of pharmacokinetics and pharmacodynamics. Schatzberg A.F., Nemeroff C.B. Textbook of Psychopharmacology. The American Psychiatric Press Textbook of Psychopharmacology. 2nd Edition: 1998;155-169 American Psychiatric Press, Washington, DC.
17. Draper B.M. The effectiveness of the treatment of depression in the physically ill elderly. Aging Ment. Health. 4:2000;9-20.
18. Fava M., Judge R., Hoog S.L., Nilson M.E., Koke S.C. Fluoxetine versus sertraline and paroxetine in major depressive disorder: change in weight with long-term treatment. J. Clin. Psychiatry. 61:2000;863-867.
19. Glassman A.H., O'Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T. Jr., Krishnan K.R., van Zyl L.T., Swenson J.R., Finkel M.S., Landau C., Shapiro P.A., Pepine C.J., Mardekian J., Harrison W.M., Barton D., McIvor M. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. J. Am. Med. Assoc. 288:2002;701-709.
20. Guelfi, J.D., Anseau, M., Timmerman, L., Kørsgaard, S., The Mirtazapine-Venlafaxine Study Group, 2001. Mirtazapine versus venlafaxine in hospitalised severely depressed patients with melancholic features. J. Clin. Psychopharmacol. 21, 425-431.
21. Hirschfeld R.M.A. Care of the sexually active depressed patient. J. Clin. Psychiatry. 60:(Suppl. 17):1999;32-36.
22. Keller M.B. Long-term treatment of recurrent and chronic depression. J. Clin. Psychiatry. 61:(Suppl. 24):2001;3-5.
23. Kjernisted et al., 2002. Mirtazapine (orally disintegrating tablet) versus sertraline: a prospective onset-of-action trial. Int J Neuropsychopharmacol 5(Suppl 1), S140.
24. Leinonen, E., Skarstein, J., Behnke, K., Ågren, H., Helsdingen, J.T., The Nordic Antidepressant Study Group, 1999. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomised study in patients with major depressive disorder. Int. Clin. Psychopharmacol. 14, 329-337.
25. Michelson D., Amsterdam J.D., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Zajecka J., Sundell K.L., Kim Y., Beasley C.M. Changes in weight during a 1-year trial fluoxetine. Am. J. Psychiatry. 156:1999;1170-1176.
26. Montejo-Gonzales A.L., Llorca G., Izquierdo J.A., Antidepressant induced sexual dysfunction: a multicentre and prospective study using a questionnaire of 693 patients. Poster presented at the 152nd Annual Meeting of the American Psychiatric Association; May 1999, Washington DC, USA.
27. Montgomery S.A. Safety of mirtazapine: a review. Int. Clin. Psychopharmacol. 10:(Suppl. 4):1995;37-45.
28. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl. 391:1997;31-37.
29. Pampallona S., Bollini P., Tibaldi G., Kupelnick B., Munizza C. Patient adherence in the treatment of depression. Br. J. Psychiatry. 180:2002;104-109.
30. Preskorn S.H. Pharmacokinetics of antidepressants: how and why they are important to treatment. J. Clin. Psychiatry. 54:(Suppl. 9):1993;14-34.
31. Preskorn S.H. Clinical Pharmacology of Selective Serotonin Inhibitors. 1996;Professional Communications, Caddo, OK.
32. Preskorn S.H., Burke M., Harvey A., Carmichael C., Polypharmacy in psychiatry. Poster presented at 129th NCDEU Meeting, May 1999, Boca Raton, FL, USA.
33. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J. Clin. Psychiatry. 55:(Suppl. A):1994;34-39.
34. Richelson E. Synaptic effects of antidepressants. J. Clin. Psychopharmacol. 16:(Suppl. 2):1996;1S-7S.
35. Roose S.P., Glassman A.H. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J. Clin. Psychiatry. 50:(Suppl.):1989;1-18.
36. Roose S.P., Lagrissi-Thode F., Kennedy J.S., Nelson J.C., Bigger T., Pollock B.G., Gaffney A., Narayan M., Finkel H.S., McCafferty J., Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. J. Am. Med. Assoc. 279:1998;287-291.
37. Roose S.P., Holland P.J., Hassman H.A., Rosenthal M. Multi-site, open label, observational study of the effectiveness and safety of mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age. Poster Presented at the 15th ECNP Congress, October 5-9, Barcelona, Spain: 2002.
38. Salzman C. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. J. Clin. Psychiatry. 60:(Suppl. 20):1999;30-33.
39. Simon G.E., Von Korff M., Wagner E.H., Barlow W. Patterns of antidepressant use in community practice. Gen. Hosp. Psychiatry. 15:1993;399-408.
40. Schatzberg A., Kremer C., Rodrigues H.E., DeBattista C., Murphy Jr. G.M. and the Mirtazapine vs Paroxetine Study group, 2002. Mirtazapine vs paroxetine in elderly patients. Am J Geriatr Psychiatry 10, 541-550.
41. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry. 59:1998;502-508.
42. Thase, M.E., Nierenberg, A.A., Keller, M.B., Panagides, J., For The Relapse Prevention Study Group, 2001. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry 62, 782-788.
43. Venlafaxine Monograph, www.rxlist.com/cgi/generic/venlafax_pi.htm (accesses October 25, 2002).
44. von Moltke L.l., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15:1995;125-131.
45. Wheatley, D.P., van Moffaert, M., Timmerman, L., Kremer, C.M.E., The Mirtazapine-Fluoxetine Study Group, 1998. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J. Clin. Psychiatry 59, 306-312.
46. Wolf M.E., Bukowski E.D., Conran J. Polypharmacy: a problem of the decade of the nineties. 148th APA meeting, May 20-25, Miami: 1995.